Wealth Enhancement Advisory Services LLC Sells 3,584 Shares of Aura Biosciences, Inc. $AURA

Wealth Enhancement Advisory Services LLC trimmed its position in Aura Biosciences, Inc. (NASDAQ:AURA) by 23.2% in the second quarter, according to its most recent filing with the SEC. The fund owned 11,853 shares of the company’s stock after selling 3,584 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Aura Biosciences were worth $78,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of AURA. GAMMA Investing LLC lifted its stake in shares of Aura Biosciences by 5,766.9% in the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company’s stock valued at $57,000 after acquiring an additional 9,573 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new stake in Aura Biosciences in the first quarter valued at $151,000. Regency Capital Management Inc. DE increased its holdings in Aura Biosciences by 23.0% in the first quarter. Regency Capital Management Inc. DE now owns 749,482 shares of the company’s stock valued at $4,392,000 after purchasing an additional 140,058 shares during the period. Levin Capital Strategies L.P. increased its holdings in Aura Biosciences by 9.1% in the first quarter. Levin Capital Strategies L.P. now owns 1,360,768 shares of the company’s stock valued at $7,974,000 after purchasing an additional 113,149 shares during the period. Finally, Nuveen LLC acquired a new stake in Aura Biosciences in the first quarter valued at $561,000. 96.75% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Aura Biosciences news, SVP Amy Elazzouzi sold 7,722 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $6.70, for a total transaction of $51,737.40. Following the completion of the sale, the senior vice president directly owned 86,558 shares in the company, valued at approximately $579,938.60. This trade represents a 8.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 6.30% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on AURA. Weiss Ratings restated a “sell (d-)” rating on shares of Aura Biosciences in a report on Wednesday, October 8th. Zacks Research upgraded Aura Biosciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 19th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Aura Biosciences Trading Down 1.8%

Shares of Aura Biosciences stock opened at $5.92 on Monday. The business has a 50-day moving average price of $6.37 and a two-hundred day moving average price of $6.17. Aura Biosciences, Inc. has a 1-year low of $4.34 and a 1-year high of $12.38. The company has a market cap of $367.75 million, a P/E ratio of -3.02 and a beta of 0.45.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Equities research analysts forecast that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.